LatinX/HIspanic Attitudes and Perspectives on Investigations and Studies- of New Drugs: LAPIS-ND.
FDA 1U01FD007777Aug 16, 2022 - Aug 15, 2023
Role: Principal Investigator
Description: Participation of older adults self-described as Hispanic/Latino are amongst the lowest in clinical trials, yet Hispanic/Latinos compose rapidly growing segments of the U.S. and clinical populations. Their voice, concerns, desired outcomes, perceived incentives and barriers to participation are key to increasing their representation in the evaluation of new medical therapies. Our overall goal is to understand their perceptions about research, clinical trials, and obstacles, facilitators and priorities regarding participation in clinical trials by conducting focus groups with older Hispanics of Mexican origin. |
The MUM study: MUltimorbidity and Medications: the unheard perspective of older adults
UCSF-Stanford CERSI (FDA) 2U01FD005978 Project #64 -Sep 1, 2021 - Aug 31, 2023
Role: Principal Investigator
Description: The goal is to hear the voice of “typical” older adults with multiple chronic conditions and any care partners to understand their perceptions about prescription drugs, medication safety, risk, pre-marketing evaluation—obstacles, facilitators and priorities regarding clinical trial participation, desired patient-centered outcomes and feasibility of performance and data collection (personal vs. digital). The goal is to conduct a survey of representative older adults with multimorbidity |
Principal Investigator, FDA: 2U01The MUM-URMA1 study: Multimorbidity and Medications: the unheard perspective of older Under-Represented Racial and Ethnic Minority Adults-phase 1
FDA 2U01FD005978-06, Project 71Sep 1, 2021
Role: Principal Investigator
Description: Participants in clinical trials should reflect the individuals who may one day receive the therapeutic agent. Ensuring people from diverse backgrounds have the ability and motivation to participate in clinical trials is key to advancing health equity and in assuring the efficacy and safety of new medical therapies in groups likely to receive the medical therapies. Older adults consume more medications than any other patient group yet are under-represented in evaluations of new medications with representation of Chinese/Chinese Americans having amongst the lowest representation. Participation of older adults self-described as Asian are amongst the lowest in clinical trials yet compose rapidly growing segments of the U.S. population and the clinical population. Their voice, concerns, desired outcomes, incentives and barriers to participation are key to increasing their representation in new therapies. |
Direct-Acting Oral Anticoagulants: Anticoagulant Activity in Understudied Older NVAF Patients
NIH R21AG067463Apr 15, 2020 - Mar 31, 2022
Role: Principal Investigator
Description: The goal is to hear the voice of “typical” older adults with multiple chronic conditions and any care partners to understand their perceptions about prescription drugs, medication safety, risk, pre-marketing evaluation—obstacles, facilitators and priorities regarding clinical trial participation, desired patient-centered outcomes and feasibility of performance and data collection (personal vs. digital). The goal is to conduct a survey of representative older adults with multimorbidity |
Patient Perspectives on Adherence to Eliquis Use. (P.I., UCLA
ARISTA-USA: American ThRombosis InveStigator IniTiated Research ProgrAm-USA N.A.Mar 26, 2020 - Mar 26, 2023
Role: Co-investigator
Description: The goal of the study is to determine why patients stop or do not start newer anticoagulant medications. |
Patient perspectives on primary nonadherence to statins
NIA R21AG055832-01Jun 1, 2017 - May 31, 2020
Role: Co-investigator |
Prevalence and Knowledge of Concurrent OTC Drug / Dietary Supplement- Eliquis Use.
BMS/Pfizer. ARISTA-USA NAApr 1, 2016 - Dec 31, 2019
Role: Co-investigator |
Distribution of free 25-OH D concentrations in clinical populations: normal and diseases states
Future Diagnostics, BV and Diasource Inc. NAMar 2, 2015 - Jun 29, 2018
Role: Principal Investigator |
Optimizing vitamin D in the elderly
NIH R21AG041660Aug 15, 2012 - Jul 31, 2015
Role: Principal Investigator |
Improving Medication Therapy for Older Patients with Common Co-morbidities
NIH RC1AG036377Sep 30, 2009 - Aug 31, 2012
Role: Principal Investigator |
Older Persons &Drugs: race, gender, and age effects
NIH R56AG015982Sep 1, 1999 - Aug 31, 2011
Role: Principal Investigator |
Older Persons &Drugs: race, gender, and age effects
NIH R01AG015982Sep 1, 1999 - Sep 15, 2010
Role: Principal Investigator |
GERIATRIC LEADERSHIP ACADEMIC AWARD
NIH K07AG000768Dec 15, 1997 - Nov 30, 2002
Role: Principal Investigator |
MOLECULAR BASIS OF DRUG TRANSPORT IN THE INTESTINE
NIH R01GM057656Aug 1, 1997 - Jul 31, 2001
Role: Co-Investigator |
Research Training in Geriatric Medicine
NIH T32AG000212Sep 1, 1991 - Apr 30, 2023
Role: Co-Principal Investigator |
SMALL INSTRUMENTATION GRANT
NIH S15GM047084Jun 1, 1991 - May 31, 1992
Role: Principal Investigator |
REGULATION OF CARDIAC RHYTHM AND CONDUCTION WITH AGING
NIH R01AG009550Feb 1, 1991 - Oct 31, 1997
Role: Principal Investigator |
EFFECT OF AGING ON CALCIUM BLOCKER KINETICS/DYNAMICS
NIH R01AG005940Aug 1, 1986 - Jul 31, 1995
Role: Principal Investigator |
EFFECT OF AGING ON CALCIUM BLOCKER KINETICS/DYNAMICS
NIH K04AG000327Jan 1, 1986 - Dec 31, 1990
Role: Principal Investigator |
PHARMACOKINETICS/PHARMACODYNAMICS
NIH P50GM026691Aug 1, 1979 - Jul 31, 1998
Role: Co-Investigator |
GENERAL CLINICAL RESEARCH CENTER
NIH M01RR000048Dec 1, 1977 - May 31, 2008
Role: Co-Investigator |
GENERAL CLINICAL RESEARCH CENTER
NIH M01RR000350Dec 1, 1976 - Nov 30, 1995
Role: Co-Investigator |
General Clinical Research Center
NIH M01RR000079Dec 1, 1974 - Mar 31, 2009
Role: Co-Investigator |
Patient Perspectives on Non-Adherence to Apixaban
BMS/Pfizer. ARISTA-USA-- pending Pending
Role: Co-investigator |